174 Gruijs, M., Braster, R., Overdijk, M. B., Hellingman, T., Verploegen, S., Korthouwer, R., van der Wilk, B. J., Parren, P. W. H. I., van der Vliet, H. J., Bögels, M., & van Egmond, M. 2022. Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells. Journal of Oncology, 2022, e3577928.
173 Weerdt, I. de, Lameris, R., Scheffer, G. L., Vree, J., Boer, R. de, Stam, A. G., Ven, R. van de, Levin, M.-D., Pals, S. T., Roovers, R. C., Parren, P. W. H. I., Gruijl, T. D. de, Kater, A. P., & Vliet, H. J. van der. 2021. A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research, 9(1), 50–61.
172 Lameris, R., Ruben, J. M., Weerdt, I. de, Roovers, R., van de Donk, N. W. C. J., Broyl, A., Kater, A. P., Riedl, T., Iglesias, V., Winograd, B., Adang, A. E., de Gruijl, T. D., Parren, P. W. H. I., & Vliet, H. J. van der. 2021. Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML. Blood, 138, 2266.
171 Zwarthoff, S. A., Widmer, K., Kuipers, A., Strasser, J., Ruyken, M., Aerts, P. C., Haas, C. J. C. de, Ugurlar, D., Boer, M. A. den, Vidarsson, G., Strijp, J. A. G. van, Gros, P., Parren, P. W. H. I., Kessel, K. P. M. van, Preiner, J., Beurskens, F. J., Schuurman, J., Ricklin, D., & Rooijakkers, S. H. M. 2021. C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases. Proceedings of the National Academy of Sciences, 118(26).
170 Vergoossen, D. L. E., Plomp, J. J., Gstöttner, C., Fillié-Grijpma, Y. E., Augustinus, R., Verpalen, R., Wuhrer, M., Parren, P. W. H. I., Dominguez-Vega, E., Maarel, S. M. van der, Verschuuren, J. J., & Huijbers, M. G. 2021. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proceedings of the National Academy of Sciences, 118(13).
169 Neijssen, J., Cardoso, R. M. F., Chevalier, K. M., Wiegman, L., Valerius, T., Anderson, G. M., Moores, S. L., Schuurman, J., Parren, P. W. H. I., Strohl, W. R., & Chiu, M. L. 2021. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry, 296.
168 Strasser, J., de Jong, R. N., Beurskens, F. J., Schuurman, J., Parren, P. W. H. I., Hinterdorfer, P., & Preiner, J. 2020. Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition. ACS Nano, 14(3), 2739–2750.
167 Overdijk, M. B., Strumane, K., Beurskens, F. J., Buijsse, A. O., Vermot-Desroches, C., Vuillermoz, B. S., Kroes, T., Jong, B. de, Hoevenaars, N., Hibbert, R. G., Lingnau, A., Forssmann, U., Schuurman, J., Parren, P. W. H. I., Jong, R. N. de, & Breij, E. C. W. 2020. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Molecular Cancer Therapeutics, 19(10), 2126–2138.
166 Oostindie, S. C., van der Horst, H. J., Kil, L. P., Strumane, K., Overdijk, M. B., van den Brink, E. N., van den Brakel, J. H. N., Rademaker, H. J., van Kessel, B., van den Noort, J., Chamuleau, M. E. D., Mutis, T., Lindorfer, M. A., Taylor, R. P., Schuurman, J., Parren, P. W. H. I., Beurskens, F. J., & Breij, E. C. W. 2020. DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer Journal, 10(3), 1–13.
165 Lubbers, R., Oostindie, S. C., Dijkstra, D. J., Parren, P. W. H. I., Verheul, M. K., Abendstein, L., Sharp, T. H., de Ru, A., Janssen, G. M. C., van Veelen, P. A., van den Bremer, E. T. J., Bleijlevens, B., de Kreuk, B.-J., Beurskens, F. J., & Trouw, L. A. 2020. Carbamylation reduces the capacity of IgG for hexamerization and complement activation. Clinical & Experimental Immunology, 200(1), 1–11.
164 Koning, M. T., Vletter, E. M., Rademaker, R., Vergroesen, R. D., Trollmann, I. J. M., Parren, P., van Bergen, C. A. M., Scherer, H. U., Kiełbasa, S. M., Toes, R. E. M., & Veelken, H. 2020. Templated insertions at VD and DJ junctions create unique B-cell receptors in the healthy B-cell repertoire. European Journal of Immunology, 50(12), 2099–2101.
163 Engelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., Verploegen, S., Labrijn, A. F., Salcedo, T., Schuurman, J., Parren, P. W. H. I., & Breij, E. C. W. 2020. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine, 52, 102625.
162 Koopman, L. A., Terp, M. G., Zom, G. G., Janmaat, M. L., Jacobsen, K., Gresnigt-van den Heuvel, E., Brandhorst, M., Forssmann, U., de Bree, F., Pencheva, N., Lingnau, A., Zipeto, M. A., Parren, P. W. H. I., Breij, E. C. W., & Ditzel, H. J. 2019. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight, 4(21), e128199.
161 Kramer, C. S. M., Franke-van Dijk, M. E. I., Priddey, A. J., Pongrácz, T., Gnudi, E., Car, H., Karahan, G. E., van Beelen, E., Zilvold-van den Oever, C. C. C., Rademaker, H. J., de Haan, N., Wuhrer, M., Kosmoliaptsis, V., Parren, P. W. H. I., Mulder, A., Roelen, D. L., Claas, F. H. J., & Heidt, S. 2019. Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies. HLA, 94(5), 415–424.
160 Strasser, J., R.N. de Jong, F.J. Beurskens, G. Wang, A.J.R. Heck, J. Schuurman, P.W.H.I. Parren, P. Hinterdorfer and J. Preiner. 2019. Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces. Nano Lett. 2019 Jun 11. doi: 10.1021/acs.nanolett.9b02220. [Epub ahead of print].
159 Oostindie, S.C., H.J. van der Horst, M.A. Lindorfer, E.M. Cook. J.C. Tupitza, C.S. Zent, R. Burack, K.R. VanDerMeid, K. Strumane, M.E.D. Chamuleau, T. Mutis, R.N. de Jong, J. Schuurman, E.C.W. Breij, F.J. Beurskens, P.W.H.I. Parren and R.P. Taylor. 2019. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica 2019 Feb 21. pii: haematol.2018.207266 Epub ahead of print.
158 Van de Donk NWCJ, T. Casneuf, A. Di Cara, P.W.H.I. Parren , S. Zweegman, B. van Kessel, H.M. Lokhorst, S.Z. Usmani, S. Lonial, P.G. Richardson, C. Chiu, T. Mutis, I.S. Nijhof and A.K. Sasser. 2019. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. Br. J. Haematol.184:475-479.
157 Ugurlar, D., S.C. Howes, B-J. de Kreuk, R.I. Koning, R.N. de Jong, F.J. Beurskens, J. Schuurman, A.J. Koster, T.H. Sharp. P.W.H.I. Parren and P. Gros. 2018. Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science.359:794-797.
156 Boshuizen, J., L.A. Koopman, E.C.W. Breij, O. Krijgsman, A. Shahrabi, E. Gresnigt–van den Heuvel, M. Ligtenberg, D. Vredevoogd, K. Kemper, T. Kuilman, J-Y. Song, M. Geukes-Foppen, L. Rozeman, C. Blank, M.L. Janmaat, D. Satijn, D.S. Peeper and P.W.H.I. Parren. 2018. Cooperative elimination of heterogeneous melanomas by targeting distinct populations with an AXL-targeting antibody-drug conjugate and BRAF/MEK inhibitors. Nature Med.24:203-212.
155 Van den Bremer, E.TJ., A.F. Labrijn, R. van den Boogaard, P. Priem, K. Scheffler, J.P.M. Melis, J. Schuurman, P.W.H.I. Parren and R.N. de Jong. 2017. Cysteine-SILAC mass spectrometry enabling the identification and quantitation of scrambled interchain disulfide bonds: preservation of native heavy-light chain pairing in bispecific IgGs generated by controlled Fab-arm exchange. Anal Chem. 89:10873-10882.
154 Peipp M., D. Wesch, H-H. Oberg, S. Lutz, A. Muskulus, J.G.J. van de Winkel, P.W.H.I. Parren, R. Burger, A. Humpe, D. Kabelitz, M. Gramatzki and C. Kellner. 2017. CD20-specific immunoligands engaging NKG2D enhance γδ T cell-1 mediated lysis of lymphoma cells. Scand. J. immunol. 86:196-206.
153 Taylor R.P., M.A. Lindorfer, E.M. Cook, F.J. Beurskens, J. Schuurman , P.W.H.I. Parren, C.S. Zent, K,R. VanDerMeid, R. Burack, M. Mizuno and P. Morgan. 2017. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clin Immunol. 181:24-28.
152 Labrijn, A.F., J.I. Meesters, T.C. Nesspor, A.A. Armstrong, S. Somani, M. Bunce, M.L. Chiu, I. Altintaş, S. Verploegen, J. Schuurman and P.W.H.I. Parren. 2017. Efficient generation of bispecific murine antibodies for preclinical investigations in syngeneic rodent models. Sci. Rep. 7:2476. DOI: 10.1038/s41598-017-02823-9.
151 Wang, G., R.N. de Jong, E.T.J. van den Bremer, P.W.H.I. Parren and A.J.R. Heck. 2017. Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry. Anal. Chem. 89:4793-4797
150 Losen L., A.F. Labrijn, V.H. van Kranen-Mastenbroek, M.L. Janmaat, K.G. Haanstra, F.J. Beurskens, M. Jonker, T. Vink, B.A. ‘t Hart, M. Mané-Damas, P.C. Molenaar1, P. Martinez-Martinez, E. van der Esch, J. Schuurman, M.H. de Baets and P.W.H.I. Parren. 2017. Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. Sci. Rep. 7: 992. DOI:10.1038/s41598-017-01019-5
149 Tammen, A., S. Derer, R. Schwanbeck, T. Rösner, A. Kretschmer, F.J. Beurskens, J. Schuurman, P.W.H.I. Parren and T. Valerius. 2017. Monoclonal antibodies against Epidermal Growth Factor Receptor acquire an ability to kill tumor cells through complement activation by mutations that selectively facilitate the hexamerization of IgG on opsonized cells. J. Immunol. 198:1585-1594
148 Engelberts, P.J., M. Voorhorst, J. Schuurman, T. van Meerten, J.M. Bakker, T. Vink, W.J. Mackus, E.C. Breij, S. Derer, T. Valerius, J.G.J. van de Winkel, P.W.H.I. Parren and F.J. Beurskens. 2016. Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells. J Immunol. 197:4829-4837.
147 Cook EM, M.A. Lindorfer, H. van der Horst, S. Oostindie, F.J. Beurskens, J. Schuurman, C.S. Zent, R. Burack, P.W.H.I. Parren and R.P. Taylor. 2016. Antibodies that efficiently form hexamers upon antigen binding can induce Complement-Dependent Cytotoxicity under complement-limiting conditions. J. Immunol. 197:1762-1775.
146 Flynn M, F. Zammarchi, P.C. Tyrer, A.U. Akarca, N. Janghra, C.E. Britten, C.E. Havenith, J.N. Levy, A. Tiberghien, L.A. Masterson, C. Barry, F. d'Hooge, T. Marafioti, P.W.H.I. Parren, D.G. Williams, P.W. Howard, P.H. van Berkel and J.A. Hartley. 2016. ADCT-301, a Pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol. Cancer Ther. 15:2709-2721.
145 de Goeij BE, T. Vink, H. Ten Napel, E.C. Breij, D. Satijn, R. Wubbolts, D. Miao and P.W.H.I. Parren. 2016. Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63. Mol. Cancer Ther. 15:2688-2697.
144 Verzijl D, T. Riedl, P.W.H.I. Parren and A.F. Gerritsen.2016. A novel label-free cell-based assay technology using biolayer interferometry. Biosens Bioelectron. 87:388-395
143 Matas-Céspedes A., A.Vidal-Crespo, V. Rodriguez, N. Villamor, J. Delgado, E. Giné, H. Roca-Ho, P. Menéndez, E. Campo, A. López-Guillermo, D. Colomer, G. Roué, A. Wiestner, P.W.H.I. Parren, P. Doshi, J.J. Lammerts-van Bueren and P. Perez-Galan. 2017. The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia. Clin. Cancer Res. 23:1493-1505
142 Overdijk, M.B., J.H.M. Jansen, M. Nederend, J.J. Lammerts van Bueren, R.W.J. Groen, P.W.H.I. Parren, J.H.W. Leusen and P. Boross. 2016. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking. J. Immunol. 197:807-813
141 Wang, G., R.N. de Jong, E.T.J. van den Bremer, F.J. Beurskens, A.F. Labrijn, D. Ugurlar, P. Gros, J. Schuurman, P.W.H.I. Parren and A.J.R. Heck. 2016. Molecular basis of assembly and activation of complement component C1 in complex with Immunoglobulin G1 and antigen. Mol Cell. 63:135-145
140 Moores, S.L. M. Chiu, B.S. Bushey, K. Chevalier, L. Luistro, K. Dorn, R.J. Brezski, P. Haytko, T. Kelly, S-J. Wu, P. Martin, J. Neijssen, P.W.H.I. Parren, J. Schuurman, R. Attar, S. Laquerre, M.V. Lorenzi and G.M. Anderson. 2016. A Novel Bispecific Antibody Targeting EGFR and cMet that is effective against EGFR inhibitor- resistant lung tumors. Cancer Research. 76:3942-3953.
139 Drent, E., R.W. Groen, W.A. Noort, M. Themeli, J.J. Lammerts van Bueren, P.W.H.I. Parren, J. Kuball, Z. Sebestyen, H. Yuan, J. de Bruijn, N.W. van de Donk, A.C. Martens, H.M. Lokhorst and T. Mutis. 2016. Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 101: 616-625.
138 Moldt, B., K. Le, D.G. Carnathan, J.B. Whitney, N. Schultz, M.G. Lewis, E. Borducchi, K. Smith, J.J. Mackel, S.L. Sweat, A.P. Hodges, A. Godzik, P.W.H.I. Parren, G. Silvestri, D.H. Barouch and D.R. Burton. 2016. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. AIDS 30: 1543-1551.
137 de Jong, R.N. F.J. Beurskens, S. Verploegen, K. Strumane, M.D. van Kampen, P.J. Engelberts, S. Oostindie, M. Voorhorst, W. Horstman, G. Wang, A.J.R. Heck, J. Schuurman and P.W.H.I. Parren. 2016. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biology 14:e1002344. DOI: 10.1371/journal.pbio.1002344.
136 Lindorfer, M.A., E.M. Cook, J.C. Tupitza, C.S. Zent, R. Burack, R.N. de Jong, F.J. Beurskens, J. Schuurman, P.W.H.I. Parren and R.P. Taylor. 2016. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Mol. Immunol. 70: 13-23.
135 Kellner C, A. Günther, A. Humpe, R. Repp, K. Klausz, S. Derer, T. Valerius, M. Ritgen, M. Brüggemann, J.G.J. van de Winkel, P.W.H.I. Parren, M. Kneba, M. Gramatzki and M. Peipp. 2015. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology 5: e1058459.
134 Riedl, T., E. van Boxtel, M. Bosch, P.W.H.I. Parren and A.F. Gerritsen. 2015. High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe. J. Biomol. Screen. 21: 12-23, 2015.
133 Van den Bremer E.T. F.J. Beurskens, M. Voorhorst, P.J. Engelberts, R.N. de Jong, B.G. van der Boom, E.M. Cook , M.A. Lindorfer, R.P. Taylor , P.H. van Berkel and P.W.H.I. Parren. 2015. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. mAbs 7:672-680.
132 Dyachenko A, G. Wang, M. Belov, A. Makarov, R.N. de Jong, E.T. van den Bremer, P.W.H.I. Parren, A.J. Heck. Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion Da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector. 2015. Anal Chem. 87: 6095-6102.
131 Oostendorp M, J.J. Lammerts van Bueren, P. Doshi, I. Khan, T. Ahmadi, P.W.H.I. Parren, W.W. van Solinge, K.M. de Vooght. 2015. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 55:1555-1562.
130 De Goeij, B.E.C.G., D. Satijn, C.M. Freitag, R. Wubbolts, W.K. Bleeker, A. Khasanov, T. Zhu, G. Chen, D. Miao, P.H.C. van Berkel, and P.W.H.I. Parren. 2015. High turnover of Tissue Factor enables efficient intracellular delivery of Antibody–Drug Conjugates. Mol. Cancer Ther. 14: 1130-1140.
129 Overdijk, M.B. S. Verploegen, M. Bögels, M. van Egmond, J.J. Lammerts van Bueren, T. Mutis, R.W.J. Groen, A.C.M. Martens, W.K. Bleeker and P.W.H.I. Parren. 2015. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 7: 311-321.
128 Nijhof, I.S., J. Lammerts van Bueren, B. van Kessel, P. Andre, Y. Morel, H.M. Lokhorst, N. van de Donk, P.W.H.I. Parren and T. Mutis. 2015. Daratumumab-mediated lysis of primary multiple myeloma (MM) cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica, 100: 263-268.
127 Nijhof, I.S., R.W.J. Groen, W.A. Noort, B. van Kessel, J. Lammerts van Bueren, R. de Jong-Korlaar, J. Bakker, P.W.H.I. Parren, H.M. Lokhorst, N.W.C.J. van de Donk, A.C.M. Martens and T. Mutis. 2015. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin. Cancer Res. 21:2802-2810
126 Da Roit F., P.J. Engelberts, R.P. Taylor, E.C. Breij, G. Gritti, A. Rambaldi, M. Introna, P.W.H.I. Parren, F.J. Beurskens and J. Golay. 2015. Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 100:77-86.
125 Labrijn AF, J.I. Meesters, P. Priem, R.N. de Jong, E.T.J. van den Bremer, M.D. van Kampen, A.F. Gerritsen, J. Schuurman and P.W.H.I. Parren. 2014. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nature Protocols 9:2450-2463.
124 Diebolder, C.A., F.J. Beurskens, R.N. de Jong, R.I. Koning, K. Strumane, M.A. Lindorfer, M. Voorhorst, D. Ugurlar, S.Rosati, A.J.R. Heck, J.G.J. van de Winkel, I.A. Wilson, A.J. Koster, R.P. Taylor, E. Ollmann Saphire, D.R. Burton, J. Schuurman, P. Gros and P.W.H.I. Parren. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343:1260-1263.
123 De Goeij, B.E.C.G., M. Peipp, S. de Haij, E.N. van den Brink, C. Kellner, T. Riedl, R. de Jong, T. Vink, K. Strumane, W.K. Bleeker and P.WHI Parren. 2014. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. mAbs. 6: 392-402.
122 Breij, E.C.W., B.E.C.G. de Goeij, S. Verploegen, D.H. Schuurhuis, A. Amirkhosravi, J. Francis, V. Breinholt Miller, M. Houtkamp, W.K. Bleeker, D. Satijn and P.W.H.I. Parren. 2014. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 74:1214-1226.
121 Gramer, M.J., E.T.J. van den Bremer, M.D. van Kampen, A. Kundu, P. Kopfmann, E. Etter, D. Stinehelfer, J. Long, T. Lannom, E.H. Noordergraaf, J. Gerritsen, A.F. Labrijn, J. Schuurman, P.H.C. van Berkel and P.W.H.I. Parren. 2013. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large scale manufacturing by application of standard approaches. mAbs, 5: 962–973.
120 Rosati, S., E.T.J. van den Bremer, J. Schuurman, P.W.H.I. Parren, J.P. Kamerling and A.J. R. Heck. 2013. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. mAbs 5: 517-524
119 Boross, P., S. Lohse, M. Nederend, J.H.M. Jansen, G. van Tetering, M. Dechant, M. Peipp, L. Royle, L.P. Liew, L. Boon, N. van Rooijen, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius and J.H.W. Leusen. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol. Med. 5:1213-1226
118 Labrijn A.F., J.I. Meesters, B.E. de Goeij, E.T. van den Bremer, J. Neijssen, M.D. van Kampen, K. Strumane, S. Verploegen, A. Kundu, M.J. Gramer, P.H.C. van Berkel, J.G.J. van de Winkel, J. Schuurman, and P.W.H.I. Parren. 2013. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. USA. 110:5145-5150.
117 Rose, R.J., P.H.C. van Berkel, E.T.J. van den Bremer, A.F. Labrijn, T. Vink, J. Schuurman, A.J.R. Heck and P.W.H.I. Parren. 2013. Mutation of Y407 in the CH3 Domain Dramatically Alters Glycosylation and Structure of Human IgG. mAbs 5:219-228.
116 Rispens, T., J. Meesters, T.H. den Bleker, P. Ooijevaar-De Heer, J. Schuurman, P.W.H.I. Parren, A. Labrijn, and R.C. Aalberse. 2013. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Mol. Immunol. 53:35-42.
115 Glorius, P., A. Baerenwaldt, C. Kellner, M. Staudinger, M. Dechant, M. Stauch, F. J. Beurskens, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius, A. Humpe, R. Repp, M. Gramatzki, F. Nimmerjahn and M. Peipp. 2013. The novel tribody [(CD20)2xCD16] potently triggers effector cell-mediated lysis of normal and malignant B cells. Leukemia 27:190-201.
114 Engelberts, P.J., C. Badoil, F.J. Beurskens, D. Boulay-Moine, K. Grivel, P.W.H.I. Parren and M. Moulard. 2013. A quantitative flow cytometric assay to study the binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab. J Immunol Methods. 388: 8-17.
113 Overdijk, M.B., S. Verploegen, A. Ortiz Buijsse, T. Vink, J.H. Leusen , W.K. Bleeker and P.WH.I. Parren. 2012. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189:3430-3438.
112 Ball, C., B. Fox, S. Hufton, G. Sharp, S. Poole, R. Stebbings, D. Eastwood, L. Findlay, P.W.H.I. Parren, R. Thorpe, A. Bristow and S.J. Thorpe. 2012. Antibody C region influences TGN1412-like functional activity in vitro. J Immunol. 189:5831-5840.
111 Kellner, C., T. Maurer, D. Hallack, R. Repp, J.G.J. van de Winkel, P.W.H.I. Parren, T. Valerius, A. Humpe, M. Gramatzki and M. Peipp. 2012. Mimicking an induced self phenotype by coating lymphomas with the Nkp30 ligand B7-H6 promotes NK cell cytotoxicity. J. Immunol. 189: 5037-5046.
110 Bangsgaard, N., M. Houtkamp, D.H. Schuurhuis, P.W.H.I. Parren, O. Baadsgaard, H.W.M. Niessen and L. Skov. 2012. Neutralization of IL 8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor; a proof-of-principle study in human volunteers. PLoS One. 2012;7(6):e39706. doi: 10.1371/journal.pone.0039706
109 Groen, R.W.J. , W.A. Noort, R.A Raymakers, H-J. Prins, L. Aalders, F.M. Hofhuis, P. Moerer, J.F. van Velzen, A.C. Bloem, B. van Kessel, H. Rozemuller, E. van Binsbergen, A. Buijs, H. Yang, J.D. de Bruijn, M. de Weers, P.W.H.I. Parren, J.J. Schuringa, H.M Lokhorst, T. Mutis and A.C.M. Martens. 2012. Reconstructing the human hematopoietic niche in immune deficient mice creates opportunities for studying (malignant) hematopoiesis. Blood 120:e9-e16.
108 Moldt, B., M. Shibata-Koyama, E,G. Rabasz, N. Schultz, Y. Kanda, D.C. Dunlop, S.L. Finstad, C. Jin, G. Landucci, M.D. Alpert, A-S. Dugast, P.W.H.I. Parren, F. Nimmerjahn, D.T. Evans, G. Alter, D.N. Forthal, J.E. Schmitz, S. Iida, P. Poignard, D.I. Watkins, A.J. Hessell and D.R. Burton. 2012. A non-fucosylated variant of the anti-HIV-1 MAb b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but not improved protection against mucosal SHIV challenge in macaques. J. Virol. 86: 6189-6196.
107 Derer, S., S. Berger, M. Schlaeth, T. Schneider-Merck, K. Klausz , S. Lohse , M.B. Overdijk, M. Dechant, C. Kellner, I. Nagelmeier, A.H. Scheel., J.J. Lammerts van Bueren, J.G.J. van de Winkel, P.W.H.I. Parren, M. Peipp and T. Valerius. 2012. Oncogenic KRAS impairs EGFR antibodies’ efficiency by C/EBPb-dependent suppression of EGFR expression. Neoplasia 14: 190-205.
106 Kalay, H., M. Ambrosini, P.H.C. van Berkel, P.W.H.I. Parren, Y. van Kooyk, and J.J. García Vallejo. 2012. Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. Anal. Biochem. 423: 153-162.
105 Beurskens, F.J., M.A. Lindorfer, M. Farooqui, P.V. Beum, P. Engelberts, W.J.M. Mackus, P.W.H.I. Parren, A. Wiestner and R.P. Taylor. 2012. Exhaustion of cytotoxic effector systems may limit mAb-based immunotherapy in cancer patients. J. Immunol. 188:3532-3541.
104 Van der Veer, M.S., M. de Weers, J.M. Bakker, S. Wittebol, P.W.H.I. Parren, H.M. Lokhorst and T. Mutis. 2011. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer Journal 1: e41; doi:10.1038/bcj.2011.42
103 Boross, P., J.H. M. Jansen, S. de Haij, F.J. Beurskens, C.E. van der Poel, L. Bevaart, M. Nederend, J. Golay, J.G.J. van de Winkel, P.W.H.I. Parren and J.H.W. Leusen. 2011. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96:1822-1830.
102 Kap Y.S., J. Bauer, N. van Driel, W.K. Bleeker, P.W.H.I. Parren, E-J. Kooi, J.J. Geurts, J.D. Laman, J.L. Craigen, E. Blezer and B.A. ’t Hart. 2011. B-cell depletion attenuates white and grey matter pathology in marmoset experimental autoimmune encephalomyelitis. Journal of Neuropathol. Exp. Neurol. 70:992-1005.
101 Kellner, C., D. Hallack, P. Glorius, M. Staudinger, S. Mohseni Nodehi, M. de Weers, J.G.J. van de Winkel, P.W.H.I. Parren, M. Stauch, T. Valerius, R. Repp, A. Humpe, M. Gramatzki and M. Peipp. 2011. Fusion proteins between ligands for NKG2D and CD20-directed single chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis. Leukemia, 26:830-834.
100 Repp, R., C. Kellner, A. Muskulus, M. Staudinger, S. Mohseni Nodehi, P. Glorius, D. Akramiene, M. Dechant, G. Fey, P.H.C. van Berkel, J.G.J. van de Winkel, P.W.H.I. Parren, T. Valerius, M. Gramatzki and M. Peipp. 2011. Combined Fc-protein and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16 a binding but does not further enhance NK-cell mediated ADCC. J.Immunol.Methods 373:67-78.
99 Beum, P.V., E.M. Peek, M.A. Lindorfer, F.J. Beurskens, P.J. Engelberts, P.W.H.I. Parren, J.G.J. van de Winkel and R.P. Taylor. 2011. Loss of CD20 surface expression on B cells opsonized with CD20 antibodies occurs more rapidly due to trogocytosis mediated by Fc Receptor-expressing effector cells than due to direct internalization by the B cells. J Immunol. 187:3438-3447.
98 Overdijk, M.B., S. Verploegen, J.H. van den Brakel, J.J. Lammerts van Bueren, T. Vink, J.G.J. van de Winkel, P.W.H.I. Parren, W.K. Bleeker. 2011. Epidermal Growth Factor Receptor (EGFR) antibody-induced Antibody-Dependent Cellular Cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 187:3383-3390.
97 Labrijn, A.F., T. Rispens, J. Meesters, R.J. Rose, T.H. den Bleker, S. Loverix, E.T.J. van den Bremer, J. Neijssen, T. Vink, I. Lasters, R.C. Aalberse, A.J.R. Heck, J.G.J. van de Winkel, J. Schuurman and P.W.H.I. Parren. 2011. Species-specific determinants in the immunoglobulin CH3 domain enable Fab-arm exchange by affecting the non-covalent CH3-CH3 interaction strength. J Immunol. 187:3238-3246.
96 Du, S.X., L. Xu, W. Zhange, S. Tang, R.I. Boenig, H. Chen, E.B. Mariano, M.B. Zwick, P.W.H.I. Parren, D.R. Burton, T.Wrin, C.J. Petropoulos, J.A. Ballantyne, M. Chambers and R.G. Whalen. 2011. A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. PLoS One. 2011;6(6):e20927. Epub 2011 Jun 29
95 Kellner, C., W.K. Bleeker, J.J. Lammerts van Bueren, M. Staudinger, K. Klausz, S. Derer, P. Glorius, A. Muskulus, B.E.C.G. de Goeij, J.G.J. van de Winkel, P.W.H.I. Parren, T. Valerius, M. Gramatzki and M. Peipp. 2011. Human kappa light chain targeted Pseudomonas exotoxin A – identifying human antibodies and Fab fragments with favorable characteristics for antibody drug-conjugate development. J Immunol Methods. 371:122-133.
94 Klausz, K., S. Berger, S. Derer, J.J. Lammerts van Bueren, S. Lohse, M. Dechant, J.G.J. van de Winkel, M. Peipp, P.W.H.I. Parren and T. Valerius. 2011. Complement-mediated tumor-specific cell lysis by antibody combinations targeting the epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science. 102:1761-1768.
93 Rose, R.J., A.F. Labrijn, E.T.J. van den Bremer, S. Loverix , I. Lasters, P.H. C. van Berkel, J.G.J. van de Winkel, J. Schuurman, P.W.H.I. Parren and A.J.R. Heck. 2011. Quantitative analysis of the interaction strength and dynamics of human IgG4 half-molecules by native mass spectrometry. Structure 19:1274-1282.
92 Lammerts van Bueren J.J., T. Rispens, S. Verploegen, T. van der Palen-Merkus, S. Stapel, L.J. Workman, H. James, P.H.C. van Berkel, J.G.J. van de Winkel, T.A.E. Platts-Mills and P.W.H.I. Parren. 2011. Anti-galactose- a -1,3-galactose IgE from allergic patients does not bind a-galactosylated glycans attached on intact therapeutic antibody Fc domains. Nat Biotechnol. 29:574-576.
91 Beum, P.V., M.A. Lindorfer, E.M. Peek, P.T.Stukenberg, M. de Weers, F.J. Beurskens, P.W.H.I. Parren, J.G.J. van de Winkel and R.P. Taylor. 2011. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes calcium influx and induces streamers. Eur. J. Immunol. 41:2436-2446
90 De Weers, W., Y-T. Tai, M. van der Veer, J.M. Bakker, T. Vink, D.C.H. Jacobs, L.A. Oomen, M. Peipp, T. Valerius, J.W. Slootstra, T. Mutis, W.K. Bleeker, K.C. Anderson, H.M. Lokhorst, J.G.J. van de Winkel, and P.W.H.I. Parren. 2011. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, effectively induces killing of multiple myeloma tumor cells and other hematological cancers. J. Immunol. 186:1840-1848.
89 Van der Veer, M., M. de Weers, B. van Kessel, J.M. Bakker, S. Wittebol, P.W.H.I. Parren, H.M. Lokhorst, and T. Mutis. 2011. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96:284-290.
88 Van Meerten, T., H. Rozemuller, S. Hol, P. Moerer, M. Zwart, A. Hagenbeek, W.J.M. Mackus, P.W.H.I. Parren, J.G.J. van de Winkel, S.B. Ebeling and A.C. Martens. 2010. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20, can effectively eliminate CD20low
expressing tumor cells that resist Rituximab mediated lysis. Haematologica 95: 2063-2071.
87 Kap, Y.S., N. van Driel, E. Blezer, P.W.H.I. Parren, W.K. Bleeker, J.D. Laman, J.L. Craigen and B.A. ’t Hart. 2010. Late B-cell depletion with a human anti-human CD20 IgG1 k mAb halts the development of experimental autoimmune encephalitis in marmosets. J. Immunol. 185:3990-4003.
86 De Haij, S., J.H.M. Jansen, P. Boross, F.J. Beurskens, J.E. Bakema, D.L. Bos, A. Martens, J.S. Verbeek, P.W.H.I. Parren, J.G.J. van de Winkel and J.H.W. Leusen. 2010. Fc receptor ITAM signalling is essential for antibody-mediated tumor immunotherapy. Cancer Res., 70: 3209-3217.
85 Schneider-Merck, T., J.J. Lammerts van Bueren, S. Berger, K. Rossen, P.H.C. van Berkel, S. Derer, T. Beyer, S. Lohse, W.K. Bleeker, M. Peipp, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius and M. Dechant. 2010. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger ADCC but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 184:512-520.
84 Gerritsen, A.F., M. Bosch, M. de Weers, J.G.J. van de Winkel and P.W.H.I. Parren. 2010. High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. J. Immunol. Methods. 352:140-146.
83 Van Berkel, P.H.C., J. Gerritsen, E. van Voskuilen, G. Perdok, T. Vink, J.G.J. van de Winkel and P.W.H.I. Parren. 2010. Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system. Biotech.& Bioengineering 105:350-357.
82 Labrijn, A.F., A.O. Buijsse, E.T.J. van den Bremer, A.Y.W. Verwilligen, W.K. Bleeker, S.J. Thorpe, J. Killestein, C.H. Polman, R.C. Aalberse, J. Schuurman, J.G.J. van de Winkel and P.W.H.I. Parren. 2009. Therapeutic IgG4 antibodies engage in Fab arm exchange with patients’ IgG4 in vivo. Nature Biotechnol 27: 767-71.
81 Pawluzckowycz, P.W., F.J. Beurskens, P.V. Beum, M.A. Lindorfer, J.G.J. van de Winkel, P.W.H.I. Parren and R.P. Taylor. 2009. Binding or submaximal C1q promotes complement dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX). Considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183: 749-758.
80 Hessell, A.J., L. Hangartner, M. Hunter, D. M. Tehrani, W.K. Bleeker, P. Poignard, P.W.H.I. Parren, P.A. Marx and D.R. Burton. 2009. Effective, low titer, antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Medicine 15: 951-954.
79 Van Berkel, P.H.C., J. Gerritsen, G. Perdok, J. Valbjørn, T. Vink, J.G.J. van de Winkel and P.W.H.I. Parren. 2009. N-linked glycosylation is an important parameter for optimal selection of cell Lines producing biopharmaceutical human IgG. Biotechnol. Prog. 25: 244-251.
78 Beurskens, F.J., S.R. Ruuls, P.J. Engelberts, T. Vink, W.J. Mackus, J.G.J. van de Winkel and P.W.H.I. Parren. 2008. Complement activation impacts B cell depletion by both type I and type II CD20 monoclonal antibodies. Blood 112: 4354-4355.
77 Beum, P.V., M.A. Lindorfer, F. Beurskens, P.T. Stukenberg, H.M. Lokhorst, A.W. Pawluczkowycz, P.W.H.I. Parren, J.G.J. van de Winkel, and R.P. Taylor. 2008. Complement activation on B lymphocytes opsonized with rituximab and ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181:822-832.
76 Dechant, M., W. Weisner, S. Berger, M.Peipp, T. Beyer, T. Schneider-Merck, J.J. Lammerts van Bueren, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel and T. Valerius. 2008. Complement-dependent tumor cell lysis triggered by combinations of EGF-R antibodies. Cancer Res. 68:4998-5003.
75 Peipp, M., J.J. Lammerts van Bueren, T. Schneider-Merck, W. Bleeker, M. Dechant, T. Beyer, R. Repp, P.H.C. van Berkel, T. Vink, J.G.J. van de Winkel, P.W.H.I. Parren and T. Valerius. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK- and PMN-effector cells. Blood 112: 2390-2399.
74 Winiaska, M., J. Bil1, E. Wilczek, G.M. Wilczynski, M. Lekka, P. J. Engelberts, W.J.M. Mackus, E. Gorska, L. Bojarski, T. Stoklosa, D. Nowis, Z. Kurzaj, M. Makowski, E. Glodkowska, T. Issat, P. Mrowka, W. Lasek, A. Dabrowska-Iwanicka, G.W. Basak, M. Wasik, K. Warzocha, M. Sinski, Z. Gaciong, M. Jakobisiak, P.W.H.I. Parren, and J. Golab. 2008. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Medicine 5: 0502-0517.
73 Skov, L., F. Beurskens, C.O. Zachariae, S. Reitamo, J. Teeling, E.P.J. Boot, D. Hudson, O. Baadsgaard, P.W.H.I. Parren, and J.G.J. van de Winkel. 2008. Interleukin-8 as an antibody therapeutic target in inflammatory disease: reduction of clinical activity by a human monoclonal antibody in Palmoplantar Pustulosis. J. Immunol. 181:669-679.
72 Peipp, M., T. Schneider-Merck, M. Dechant, T. Beyer, J.J. Lammerts van Bueren, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel, and T. Valerius. 2008. Tumor cell killing mechanisms of Epidermal Growth Factor Receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J. Immunol. 180:4338-45
71 Bleeker, W.K., M.E. Munk, W.J.M. Mackus, J.H.N. van den Brakel, M. Pluyter, M.J. Glennie, J.G.J. van de Winkel and P.W.H.I. Parren. 2008. Estimation of the dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140: 303-312.
70 Van der Neut Kolfschoten, M., J. Schuurman, M. Losen, W.K. Bleeker, P. Martínez-Martínez, E. Vermeulen, T.H. den Bleker, L. Wiegman, T. Vink, L.A. Aarden, M.H. De Baets, J.G.J. van de Winkel, R.C. Aalberse and P.W.H.I. Parren. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557
69 Hessell, A.J., L. Hangartner, M. Hunter, C.E.G. Havenith, F.J. Beurskens, J.M. Bakker, C.M.S. Lanigan, G. Landucci, D.N. Forthal, P.W.H.I. Parren, P.A. Marx, and D.R. Burton. 2007. The Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
68 Rider, D.A., C.E.G. Havenith, R. de Ridder, J. Schuurman, C. Favre, J.C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J.G.J. van de Winkel, J. Cambier, P.W.H.I. Parren, D.R. Alexander. 2007. A human CD4 monoclonal antibody for the treatment of T cell lymphoma combines inhibition of T cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 67: 9945-9953.
67 Ollmann Saphire, E., M. Montero, A. Menendez, N.E. van Houten, M. Irving, R. Pantophlet, M.B. Zwick, P.W.H.I. Parren, D.R. Burton, J.K. Scott and I.A. Wilson. 2007. Structure of a high-affinity “mimotope” peptide, bound to the HIV-1 neutralizing antibody, b12, explains it inability to elicit gp120 cross-reactive antibodies. J. Mol. Biol. 369: 696-709.
66 Oswald W.B., T.W. Geisbert, K.J. Davis, J.B. Geisbert, N.J. Sullivan, P.B. Jahrling, P.W.H.I. Parren and D.R. Burton. 2007. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3(1): e9. doi:10.1371/journal.ppat.0030009
65 Villadsen, L.S., L. Skov,T.N. Dam, F. Dagnæs-Hansen, J. Rygaard, J Schuurman, P.W.H.I. Parren, J.G.J. van de Winkel, and O. Baadsgaard. 2006. In situ depletion of CD4+ T cells in human skin by Zanolimumab. 2007. Arch. Dermatol. Res. 298: 449-455.
64 Teeling, J.L., W.J.M. Mackus, L.J.J.M. Wiegman, J.H.N. van den Brakel, S. Beers, R.R French, T. van Meerten, S. Ebeling, T. Vink, J.W. Slootstra, P.W.H.I. Parren, M.J Glennie, and J.G.J. van de Winkel. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177:362-371.
63 Lammerts van Bueren, J.L., W.K. Bleeker, H.O. Bøgh, M. Houtkamp, J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. 2006. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 66:7630-7638.
62 Zhang, M.X., M.C. Bohlman, C. Itatani, D.R. Burton, P.W.H.I. Parren, S.C. St. Jeor and T.R. Kozel. 2006. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. 74: 362-269.
61 Baslund, B., N. Tvede, B. Danneskiold-Samsoe, P. Larsson, G. Panayi, J. Petersen, L.J. Petersen, F. Beurskens, J. Schuurman, J.G.J. van de Winkel, P.W.H.I. Parren, J.A. Gracie, S. Jongbloed, F.Y. Liew, and I.B. McInnes. 2005. Targeting interleukin-15 in patients with rheumatoid arthritis (RA): a proof of concept study. Arthritis Rheum. 52: 2686-2692.
60 Bleeker, W.K., J.J. Lammerts van Bueren, H.H. van Ojik, A.F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M.A. van Dijk, J.G.J. van de Winkel, and P.W.H.I. Parren. 2004. Dual mode of action of a human anti-EGF receptor monoclonal antibody for cancer therapy. J. Immunol.;173: 4699-707
59 Teeling, J.L., R.R. French, M.S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P.W.H.I. Parren, C.E. Hack, M. Dechant, T. Valerius, J.G.J. van de Winkel and M.J. Glennie. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
58 Zwick, M.B., H.K. Komori, R.L. Stanfield, S. Church, M. Wang, P.W.H.I. Parren, R. Kunert, H. Katinger, I.A. Wilson and D.R. Burton. 2004. The long complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78: 3155-3161.
57 Villadsen, L.S., J. Schuurman, F. Beurskens, T.N. Dam, F. Dagnæs-Hansen, L. Skov, J. Rygaard, M. M. Voorhorst-Ogink, A.F. Gerrtisen, M.A. van Dijk, P.W.H.I. Parren, O. Baadsgaard, and J.G.J. van de Winkel. 2003. Resolution of psoriasis after blockade of interleukin-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112: 1571-1580.
56 Johnson, W.E., H. Sanford, L.Schwall, D.R. Burton, P.W.H.I. Parren, J.E. Robinson, and R.C. Desrosiers. 2003. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77: 9993-10003.
55 Zwick, M.B., R. Kelleher, R. Jensen, A.F. Labrijn, M. Weng, G.V. Quinnan, Jr., P.W.H.I. Parren, D.R. Burton. 2003. A novel human antibody against HIV-1 gp120 is V1, V2 and V3 loop-dependent and helps delimit the epitope of the broadly neutralizing antibody IgG1 b12. J.Virol. 77: 6965-6978.
54 Zwick, M.B., P.W.H.I. Parren, E. Ollmann Saphire, S. Church, M. Wang, J.K. Scott, P.E. Dawson, I.A. Wilson, and D.R. Burton. 2003. Molecular features of the broadly neutralizing Immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77: 5863-5876.
53 Pantophlet, R., E. Ollmann Saphire, P. Poignard, P.W.H.I. Parren, I.A. Wilson, and D.R. Burton. 2003. Fine mapping of the interaction of neutralizing and non-neutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol.77: 642-658.
52 Poignard, P., M. Moulard, E. Golez. V. Viviona, M. Franti, S. Venturini, M. Wang, P.W.H.I. Parren, and D.R. Burton, 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77: 353-365.
51 Kwong, P.D., M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, T.D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, H. Katinger, P.W.H.I. Parren, J. Robinson, D. Van Rijk, L. Wang, D.R. Burton, E. Freire, R. Wyatt, J. Sodroski, W.A. Hendrickson, J. Arthos. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
50 Schülke, N., M.S. Vesanen, R.W. Sanders, P. Zhu, M. Lu, D.J. Anselma, A.R. Villa, P.W.H.I. Parren, J.M. Binley, K.H. Roux, P.J. Maddon, J.P. Moore, W.C. Olson. 2002. Structural and antigenic properties of a proteolytically mature, disulphide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J. Virol.76: 7760-76.
49 Meissner, F., T. Maruyama, M. Frentsch, A.J. Hessell, L.L. Rodriguez, T.W. Geisbert, P.B. Jahrling, D.R. Burton, and P.W.H.I. Parren. 2002. Detection of antibodies against the four subtypes of Ebola virus in sera from any species using a novel antibody-phage indicator assay. J. Virol. 300: 236-243.
48 Parren, P.W.H.I., T.W. Geisbert, T. Maruyama, P.B. Jahrling, and D.R. Burton. 2002. Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol.76: 6408-6412.
47 Moulard, M., S. Phogat, Y. Shu, A.F. Labrijn, X. Xiao, J.M. Binley, M-Y. Zhang, I.A. Sidorov, C.C. Broder, J. Robinson, P.W.H.I. Parren, D.R. Burton, and D.S. Dimitrov. 2002. Broadly cross-reactive HIV-1 neutralizing human mono clonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc.Natl.Acad.Sci. USA 99:6913-18.
46 de Carvalho Nicacio, C., R.A.Williamson, P.W.H.I. Parren, Å. Lundkvist, D.R. Burton, and E. Björling. 2002. Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76: 251-258.
45 Zwick, M.B., M. Wang. P. Poignard, G. Stiegler, H. Katinger, D.R. Burton and P.W.H.I. Parren. 2001. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75: 12198-12208.
44 Hezareh, M., A.J. Hessell, R.C. Jensen, J.G.J. van de Winkel, and P.W.H.I. Parren. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75: 12161-12168.
43 Zwick, M.B., A.F. Labrijn, M. Wang, C. Spenlehauer, E. Ollmann Saphire, J.M. Binley, J.P. Moore, G.Stiegler, H. Katinger, D.R. Burton and P.W.H.I. Parren. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75: 10892-10905.
42 Ollmann Saphire, E., P.W.H.I. Parren, R. Pantophlet, M.B. Zwick, G.M. Morris, P.M. Rudd, R.A. Dwek, R.L. Stanfield, D.R. Burton and I. A. Wilson. 2001. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science 293:1155-1159.
41 Parren, P.W.H.I., P. Marx, A.J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J.P. Moore and D.R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
40 Zwick, M.B., L.L.C. Bonnycastle, A. Menendez, A. M.B. Irving, C.F. Barbas III, P.W.H.I. Parren, D.R. Burton, and J.K. Scott. 2001. Identification and characterization of a peptide that specifically binds the human, broadly human immunodeficiency virus type 1 antibody b12. J. Virol. 75: 6692-6699.
39 Williamson R.A., M.P. Burgoon, G. P. Owens, O. Ghausi, E. Leclerc, L. Firme, S. Carlson, J. Corboy, P.W.H.I. Parren, P.P. Sanna, D.H. Gilden and D.R. Burton. 2001. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl. Acad. Sci. USA, 98:1793-1798.
38 Ollmann Saphire, E., P.W.H.I. Parren, C.F. Barbas III, D.R. Burton, and I.A. Wilson. 2001. Crystallization and preliminary structure determination of an intact human immunoglobulin b12: An antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallographica, D57:168-171.
37 Cabezas, E., M. Wang, P.W.H.I. Parren, R. Stanfield, and A.C. Satterthwait. 2000. A structure-based approach to a synthetic vaccine for human immunodeficiency virus type 1. Biochemistry, 39:14377-91.
36 Xu, D., M-L., Alegre, S.S. Varga, A.L. Rothermel, A.M. Collins, V.L. Pulito, L.S. Hanna, K.P. Dolan, P.W.H.I. Parren, J.A. Bluestone, L.K. Jolliffe, and R.A. Zivin. 2000. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell.Immunol. 200: 16-26.
35 Dorrell, L., A.J. Hessell, M. Wang, H. Whittle, S. Sabally, S. Rowland-Jones, D.R. Burton and P.W.H.I Parren. 2000. Absence of specific mucosal antibody responses in HIV exposed uninfected sex workers from The Gambia. AIDS 14: 1117-1122.
34 Wines, B.D., M.S. Powell, P.W.H.I. Parren, N. Barnes, and P.M. Hogarth. 2000. The IgG Fc contains distinct FcR binding sites: The leukocyte receptors FcgRI and FcgRIIa bind to a region in the Fc distinct from that recognized by FcRn and protein A. J. Immunology, 164:5313-5318.
33 Burton, D.R. and P.W.H.I. Parren. 2000. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? Nature Medicine, 6:123-125.
32 Crawford, J.M., P.L. Earl, B. Moss, K.A. Reimann, M.S. Wyand, K.H. Manson, M. Bilska, J.T. Zhou, C.D. Pauza, P.W.H.I. Parren, D.R. Burton, J.G. Sodroski, N.L. Letvin and D.C. Montefiori. 1999. Characterization of primary isolate-like variants of Simian-Human immunodeficiency virus. J. Virology, 73:10199-10207.
31 Poignard, P., R. Sabbe, G.R. Picchio, M. Wang, R.J. Gulizia, H. Katinger, P.W.H.I. Parren, D.E. Mosier, and D.R. Burton. 1999. Neutralizing antibodies have limited effects of the control of established HIV-1 infection in vivo. Immunity 10: 431-438.
30 Maruyma, T., L.L. Rodriguez, P.B. Jahrling, A. Sanchez, A.S. Kahn, S.T. Nichol., C.J. Peters, P.W.H.I. Parren, and D.R. Burton. 1999. Ebola virus can be effectively neutralized by antibody produced in natural human infection.J. Virol. 73: 6024-6030.
29 Parren, P.W.H.I., M. Wang, A. Trkola, J.M. Binley, M. Purtscher, H. Katinger, J.P. Moore, and D.R. Burton. 1998. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type-1. J. Virol. 72: 10270-10274.
28 Frankel, S.S., R.M. Steinman, N.L. Michael, S. Ratto Kim, N. Bhardwaj, M. Pope, M.K. Louder, P. Ehrenberg, P.W.H.I. Parren, D.R. Burton, H. Katinger, T.C. VanCott, M.L. Robb, D.L. Birx, and J.R. Mascola. 1998. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T-cells. J. Virol. 72: 9788-9794.
27 Sullivan, N., Y. Sun., J.M. Binley, J. Lee, C. F. Barbas III, P.W.H.I. Parren, D.R. Burton, and J. Sodroski. 1998. Determinants of HIV-1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72:6332-6338.
26 LeBlanc, J.F., K.E. MacLane, P.W.H.I. Parren, D.R. Burton, and P. Ghazal. 1998. Recognition profile of a sequence specific DNA binding antibody. Biochemistry 37:6015-6022.
25 Parren, P.W.H.I., I. Mondor, D. Naniche, H.J. Ditzel, P.J. Klasse, D.R. Burton, and Q.J. Sattentau. 1998. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72:3512-3519.
24 Salonen, E-M., P.W.H.I. Parren, Y.F. Graus, Å. Lundkvist, P. Fisicaro, O. Vapalahti, H. Kallio-Kokko, A. Vaheri, and D.R. Burton. 1998. Human recombinant Puumala virus antibodies: cross-reaction with other hantaviruses and use in diagnostics. J. Gen. Virol. 79: 659-665.
23 Glamann, J., D.R. Burton, P.W.H.I. Parren, H.J. Ditzel, K.A. Kent, C. Arnold, D. Montefiori, and V.M. Hirsch. 1998. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high homologous neutralizing activity: recovery from a long-term nonprogressor SIV-infected macaque. J. Virol. 72: 585-592.
22 Gauduin, M-C., P.W.H.I. Parren, R. Weir, C.F. Barbas, D.R. Burton, and R.A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of human immunodeficiency virus type 1. Nature Medicine. 3: 1389-1393.
21 Ugolini, S., I. Mondor, P.W.H.I. Parren, D.R. Burton, S.A. Tilley, P.J. Klasse, and Q.J. Sattentau. 1997. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line adapted HIV-1 neutralization. J. Exp. Med. 186: 1287-1298.
20 Schuurman, J., G.J. Perdok, T.E. Lourens, P.W.H.I. Parren, M.D. Chapman, and R.C. Aalberse. 1997. Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p2 and its use for the absolute quantification of allergen specific IgE. J. Allergy Clin. Immunol. 99:545-550.
19 Mo, H., L. Stamatatos, J.E. Ip, C.F. Barbas, P.W.H.I. Parren, D.R. Burton, J.P. Moore, and D.D. Ho. 1997. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1 b12. J. Virol. 71: 6869-6874.
18 D'Souza, M.P., D. Livnat, J.A. Bradac, S. Bridges, the AIDS Clinical Trials Group Antibody Selection Working Group and Collaborating Investigators (The Antibody Serological Project Collaborating Investigators were: C. Barbas, Y. Bryson, D.R. Burton, M. Gorny, C. Hanson, H. Katinger, T. Matthews, T. Merigan, J. McNamara, J.P. Moore, M. Norcross, P.W.H.I. Parren, M. Posner, J. Robinson, A. Trkola, N. Virani-Ketter, and S. Zolla-Pazner). 1997. Evaluation of monoclonal antibodies to HIV-1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175: 1056-1062.
17 Parren, P.W.H.I., Q. J. Sattentau, and D.R. Burton. 1997. HIV-1 antibody - debris or virion? Nature Med. 3: 366-367 (letter).
16 Graus, Y.F., M.H. de Baets, P.W.H.I. Parren, S. Berrih-Aknin, J. Wokke, P.J. van Breda Vriesman, and D.R. Burton. 1997. Human anti-nicotinic acetylcholine receptor (AChR) recombinant Fab fragments isolated from thymus-derived phage display libraries from Myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.J. Immunol. 158:1920-1929.
15 Ditzel, H.J.*, P.W.H.I. Parren*, J.M. Binley, J. Sodroski, J.P. Moore, C.F. Barbas III, and D.R. Burton. 1997. Mapping the protein surface of HIV-1 gp120 using human monoclonal antibodies from phage display libraries. J. Mol. Biol. 267: 684-695. *Authors contributed equally.
14 Parren, P.W.H.I., P. Fisicaro, A. Labrijn, J.M. Binley, W-P. Yang, H.J. Ditzel, C. F. Barbas III, and D.R. Burton. 1996. In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 oligomer. J. Virol. 70:9046-9050.
13 Binley, J.M., H.J. Ditzel, C.F. Barbas III, N. Sullivan, J. Sodroski, P.W.H.I. Parren, and D.R. Burton. 1996. Human antibody responses to HIV-1 gp41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retrovir. 12:911-924.
12 Parren, P.W.H.I., H.J. Ditzel, R.J. Gulizia, J.M. Binley, C.F. Barbas III, D.R. Burton, and D.E. Mosier. 1995. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9:F1-F6.
11 Schuurman, J., T.E. Lourens, G.J. Perdok, P.W.H.I. Parren, and R.C. Aalberse.1995. Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p2. Int. Arch. Allergy Immunol. 107:465-466
10 Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W.H.I. Parren, L.S.W. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, M. Lamacchia, E. Garratty, E.R. Stiehm, Y.J. Bryson, Y. Cao, J.P. Moore, D.D. Ho, and C.F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 266:1024-1027.
9 Kuiper, H., M. Brouwer, M. de Boer, P.W.H.I. Parren, and R.A.W. van Lier. 1994. Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation. Eur. J. Immunol. 24:1956-1960.
8 Warmerdam, P.A.M., I.E. van den Herik-Oudijk, P.W.H.I. Parren, N.A.C. Westerdaal, J.G.J. van de Winkel, and P.J.A. Capel. 1993. Interaction of a human FcgRIIb1 (CD32) isoform with murine and human IgG subclasses. Int. Immunol. 5:239-247.
7 De Boer, M., P.W.H.I. Parren, J. Dove, F. Ossendorp, G. van der Horst, and J. Reeder. 1992. Functional characterization of a novel anti-B7 monoclonal antibody. Eur. J. Immunol. 22:3071-3075.
6 Warmerdam, P.A.M., P.W.H.I. Parren, A. Vlug, L.A. Aarden, J.G.J van de Winkel, and P.J.A. Capel. 1992. Polymorphism of the human Fcg receptor II (CD32): molecular basis and functional aspects. Immunobiol. 185:175-182.
5 Parren, P.W.H.I., P.A.M. Warmerdam, L.C.M. Boeije, J. Arts, N.A.C. Westerdaal, A. Vlug, P.J.A. Capel, L.A. Aarden and J.G.J. van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity FcgRIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90:1537-1546.
4 Parren, P.W.H.I., P.A.M. Warmerdam, L.C.M. Boeije, P.J.A. Capel, J.G.J. van de Winkel, and L.A. Aarden. 1992. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies; identification of a functional polymorphism to human IgG2 anti-CD3. J. Immunol. 148:695-701.
3 Parren, P.W.H.I., M.E.J. Geerts, L.C.M. Boeije, and L.A. Aarden. 1991. Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies. Res. Immunol. 142:749-763.
2 Rijsewijk, F., M. Schuermann, E. Wagenaar, P.W.H.I. Parren, D. Weigel, and R. Nusse. 1987. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 50:649-657.
1 De Wind, N., P.W.H.I. Parren, A. Stuitje, and M. Meijer. 1987. Evidence for the involvement of the 16 kD gene promoter in initiation of chromosomal replication of Escherichia coli strains carrying a B/r-derived replication origin. Nucleic Acids Res. 15: 4901-4914.